Dimos Katsaros

Dimos Katsaros


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2022 in JMIR Cancer
Verified
Journal Article
Open access
DKDimos Katsaros
Dimos Katsaros
JHJames Hawthorne
James Hawthorne
JPJay Patel
Jay Patel
KPKaitlin Pothier
Kaitlin Pothier
TATimothy Aungst
Timothy Aungst
CFChris Franzese
Chris Franzese
Increased cancer prevalence and survival rates coupled with earlier patient discharges from hospitals have created a greater need for social support. Cancer care is both short term and long term, requiring acute treatments, treatments for remission, and long-term screenings and treatment regimens. Health care systems are already overwhelmed and often struggle to provide social support systems for everyone. Caregivers are limited in number, and even when they are available, they often lack necessary information, skills, or resources to meet the needs of patients with cancer. The act of caregiving presents various challenges, and caregivers themselves often need social support as well. Despite these needs, most social support programs are targeted toward patients alone. Given the prevalence of cancer and known needs of these patients and their caregivers, the ability to identify those who need social support is crucial. Further, the scalability and overall availability of social support programs is vital for successful patient care. This paper establishes the benefits of social support for both patients and caregivers coping with cancer treatments, explores innovative ways of identifying patients who may need social support using digital tools, and reviews potential advantages of digital social support programs.

1 August 2025 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
CFChris Franzese
Chris Franzese
JHJames Hawthorne
James Hawthorne
DKDimos Katsaros
Dimos Katsaros
MCMarty Coyne
Marty Coyne
Purpose: Subcutaneous (SC) administration is largely established as the preferred route to deliver biotherapeutics. Although the majority of approved SC products are limited to dose volumes ≤ 2.25 mL, there has been increasing industry focus on large-volume SC (LVSC) development. To date, however, there are few LVSC biotherapeutics available for self-administration, and subcutaneous immunoglobulin (SCIg) remains the most established example. As a result, there is limited published literature on real-world practices with LVSC therapies to inform user needs and preferences for delivery device design attributes. Patients and Methods: This was a remote ethnography study of patients self-administering SCIg at home for treatment of primary immunodeficiency diseases (PIDD). Participants passively video recorded their preparation and infusion processes, took photos, and provided open responses to illustrate their overall experiences with their disease, infusions, and delivery devices. Qualitative data were compiled, analyzed, and grouped into themes and subthemes that represented participant responses and sentiments. Results: A total of 11 patients completed the remote study, all of whom were diagnosed with PIDD. Enrolled participants were currently infusing SCIg with one of five delivery devices and most also had previous experience with another delivery device. Emerging themes included universal preference for SC administration and pain points associated with managing medication/supply orders, storing medications/supplies, troubleshooting device issues, performing burdensome medication preparations, priming tubing/needles, inserting/securing needles, programming devices, adapting to device volume constraints, and loading reservoirs or tubing into delivery devices. Conclusion: Although patients prefer LVSC administration at home compared to the alternatives, the current SCIg use process presents a variety of challenges. While not all of these factors will apply to every LVSC scenario, these insights, along with their corresponding implications for device design, provide a framework to inform user needs for LVSC self-administration, anticipate obstacles during development of new LVSC therapies, and improve existing delivery devices.

27 May 2022 in Expert Opinion on Drug Delivery
Verified
Journal Article
Open access
JHJames Hawthorne
James Hawthorne
DKDimos Katsaros
Dimos Katsaros
ARAmy Rinaldi
Amy Rinaldi
KBKatherine Brigham
Katherine Brigham
MDMatthew D’aUria
Matthew D’aUria
MCMarty Coyne
Marty Coyne
Self-injected biologic therapies have gained significant prevalence across numerous therapeutic areas. A lack of specific guidance on best practices may lead to inadequate biologic initiation and t...

7 January 2022 in JMIR Preprints
Verified
Preprint
Open access
DKDimos Katsaros
Dimos Katsaros
JHJames Hawthorne
James Hawthorne
JPJay Patel
Jay Patel
KPKaitlin Pothier
Kaitlin Pothier
TATimothy Aungst
Timothy Aungst
CFChris Franzese
Chris Franzese
UNSTRUCTURED Increased cancer prevalence and survival rates coupled with earlier patient discharges from hospitals have created a greater need for social support. Cancer care is both short term and long term, requiring acute treatments, treatments for remission, and long-term screenings and treatment regimens. Health care systems are already overwhelmed and often struggle to provide social support systems for everyone. Caregivers are limited in number, and even when they are available, they often lack necessary information, skills, or resources to meet the needs of patients with cancer. The act of caregiving presents various challenges, and caregivers themselves often need social support as well. Despite these needs, most social support programs are targeted toward patients alone. Given the prevalence of cancer and known needs of these patients and their caregivers, the ability to identify those who need social support is crucial. Further, the scalability and overall availability of social support programs is vital for successful patient care. This paper establishes the benefits of social support for both patients and caregivers coping with cancer treatments, explores innovative ways of identifying patients who may need social support using digital tools, and reviews potential advantages of digital social support programs.